Factors associated with longer PFS were Grade III and shorter DxTime.

In contrast, high ROR1 expression confers longer PFS to chemotherapy in the same group of patients.

The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy.

Conclusions: In a retrospective study of patients with pNETs, we found a significant association between metformin use and longer PFS.

Conclusions: Chemotherapy induced change in COX-2 expression from positivity to negativity predominantly among clinical responders and is associated with longer PFS.

At the 6-week landmark analysis, irAEs of any grade was confirmed an independent predictor of higher ORR, longer PFS, and longer OS.

Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated.

Patients with grade 2-4 rash achieved a significantly better ORR, longer PFS, and OS than those with grade 0-1 rash.

Patients for whom IL6 was not detected at baseline had longer PFS versus patients for whom it was detected (HR 0.4; P = 0.028).